期刊文献+

Beclin1与UCH-L5及LC3在急性髓系白血病中的表达及作用研究

Expression and Role of Beclin1 and UCH-L5 and LC3 in Acute Myeloid Leukemia
下载PDF
导出
摘要 目的研究基因Beclin1、UCH-L5、LC3在急性髓系白血病患者体内表达情况及作用。方法选取AML患者80例,进行危险度分层,将患者分组为初发组40例,提起骨髓液,缓解组40例,经化学诱导和药物治疗达到完全缓解后提取骨髓液,选取健康组40例,对比3种基因在不同危险度分层和健康组、初发组、完全缓解组之间的表达差异。对比不同危险度之间自噬相关基因的mRNA表达差异。分别采用自噬抑制剂、诱导剂、AML化疗药物处理治疗前骨髓液样本,检测并对比三基因表达情况。mRNA表达采用实时荧光定量PCR技术检测。结果 Beclin1、UCH-L5、LC3基因表达同危险度分层具有关联,且随危险度分级升高而升高(P <0. 05),初发组与和健康组比较,3种基因表达提高,缓解组与初发组比较,3种基因表达降低,差异具有统计学意义(P <0. 05)。自噬诱导剂、AML药物处理后,beclin1表达增强,UCH-L5基因表达减弱,LC-3表达增强。自噬抑制剂处理后beclin1表达减弱,UCH-L5基因表达增强,LC-3表达减弱(P<0. 05),治疗AML药物处理后beclin1表达上调UCH-L5下调,LC3上调(P <0. 05)。结论 Beclin1、UCH-L5、LC3在AML患者中呈现高表达,且与危险程度分级正相关,其表达同自噬过程关系密切,推测可通过药物调节三基因表达实现调节自噬而定目的,进而影响AML的治疗。 Objective To study the expression and function of Beclin1,UCH-L5 and LC3 in acute myeloid leukemia patients. Methods 80 patients with AML were selected and divided into 40 cases of primary group,bone marrow fluid was extracted,40 cases of remission group,after complete remission of chemical induction and drug treatment,bone marrow fluid was extracted. 40 cases of healthy group were selected and 3 genes were compared in different risk levels,health group,primary group and complete remission. The difference of mRNA expression between autophagy related genes in different risk levels was compared.Autophagy inhibitor,inducer and AML chemotherapy were used to treat bone marrow samples before treatment. The expression of three gene was detected and compared. MRNA expression was detected by real-time quantitative PCR. Results The gene expression of Beclin1,UCH-L5 and LC3 was associated with risk stratification,and increased with the risk grade( P < 0. 05). Compared with the healthy group,the expression of the 3 genes was increased,and the 3 genes were lower in the remission group than that of the primary group,and the difference was statistically significant( P < 0. 05). After autophagy inducer and AML treatment,Beclin1 expression was enhanced,UCh-L5 gene expression decreased and LC-3 expression increased. After the treatment of autophagic inhibitors,the expression of Beclin1 was weakened,the expression of UCh-L5 gene was enhanced and the expression of LC-3 was weakened( P < 0. 05). After treatment of AML,the expression of Beclin1 was down regulated and LC3 up regulated( P <0. 05). Conclusion Beclin1,UCH-L5 and LC3 are highly expressed in AML patients are positively related to the risk degree classification. The expression is closely related to the autophagy process. It is speculated that the regulation of 3 gene expression can regulate autophagy by regulating the expression of autophagy,and then affects the treatment of AML.
作者 苗玉迪 李艳春 李庆瑞 MIAO Yudi;LI Yanchun;LI Qingrui(Shaanxi Peoples Hospital,Xi'an,710068)
出处 《实用癌症杂志》 2019年第10期1574-1578,共5页 The Practical Journal of Cancer
基金 中央级公益性科研院所基本科研业务专项资金项目(编号:2016CS-69)
关键词 急性髓系白血病 自噬 BECLIN1 UCH-L5 LC3 Acute myeloid leukemia Autophagy Beclin1 UCH-L5 LC3
  • 相关文献

参考文献18

二级参考文献47

  • 1Zheng-hongQIN,Zhen-lunGU.Huntingtin processing in pathogenesis of Huntington disease[J].Acta Pharmacologica Sinica,2004,25(10):1243-1249. 被引量:18
  • 2张之南,沈悌,主编.血液病诊断与疗效标准[M].北京:科学出版社,2007,220. 被引量:16
  • 3Joshua L. Shipley,James N. Butera.Acute myelogenous leukemia[J]. Experimental Hematology . 2009 (6) 被引量:1
  • 4Luger SM.Treating the elderly patient with acute myelogenous leukemia[J].Hematology Am Soc Hematol Educ Program,2010,2010:62-69. 被引量:1
  • 5Zhao BB,Zhu Z,Xu PP,et al.Prognostic analysis of noncytogenetic factors in elderly adults with acute myeloid leukemia[J].Zhonghua Xue Ye Xue Za Zhi,2013,34(1):3-7. 被引量:1
  • 6O'Donnell MR,Altboud CN,Altman J,et al.Acute myeloid leukemia[J].J Nat1 Compr Cane Netw,2012,10(8):984-1021. 被引量:1
  • 7Ziogas DC,Voulgarelis M,intzaras E.A network metaanalysis of rando-mized controlled trials of induction treatments in acute myeloid leukemia in the elderly[J].Clin Ther,2011,33(3):254-279. 被引量:1
  • 8Juliusson G,Antunovic P,Derolf A,et al.Age and acute myeloid leu kemia:real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry[J].Blood,2009,113(8):4 179-4 187. 被引量:1
  • 9Lowenberg B,Beck J,Graux C,et al.Gemtuzumab ozogamicin as postrem ission treatment in AML at 60 years of age or more:results of a multice nter phase 3 study[J].Blood,2010,115(13):2586-2591. 被引量:1
  • 10Kantarjian H,Ravandi F,O'Brien S,et al.Intensive chemotherapy does not benefit most older patients(age 70 years or older)with acute myeloid leukemia[J].Blood,2010,116(22):4 422-4 429. 被引量:1

共引文献123

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部